10Jul
Proactive Due Diligence Considerations for Life Sciences Dealmakers
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the science itself and, as a...
By:
McDermott Will & Emery
Related
On October 10, 2019, the National Labor Relations Board issued an important decision in LA Specialty...
Read More >
We conclude our blog series on best practices in administering benefit claims with the three C’s: b...
Read More >
The iconic sports movie, Major League, premiered 30 years ago. Three decades later, nearly everyone ...
Read More >
Mergers and acquisitions in the healthcare industry have been on the upswing in recent years, and ev...
Read More >
Effective April 1, 2019, New York City employers with at least 15 employees (including interns and i...
Read More >
On December 2, 2019, the cost to request premium processing of employment-based immigrant and non-im...
Read More >